Table 4.

Effects of the GLP-1 agonist liraglutide and the GLP-2 agonist teduglutide in mice fed an HFCD

	Normal Diet	HFCD
Analyte	Vehicle twice daily	Vehicle twice daily	Liraglutide	Teduglutide
n	10	10	10	10
Body weight, g	28.7 ± 0.8****	36.0 ± 0.4	31.4 ± 0.8***	37.9 ± 0.9
Plasma glucose, mg/dl	190 ± 8*	220 ± 7	185 ± 13*	205 ± 5
Plasma insulin, ng/ml	0.76 ± 0.29	1.89 ± 0.54	0.40 ± 0.11*	0.95 ± 0.20
Plasma total cholesterol, mg/dl	141 ± 6****	297 ± 8	230 ± 16 **	279 ± 16
Plasma triglycerides, mg/dl	105 ± 3***	88 ± 3	59 ± 3****	84 ± 1
Hepatic TNFα content, pg/mla	2.50***	0.58	2.50**	3.50
Macrovesicular steatosis scorea	0.00****	4.00	1.75**	2.00*
Microvesicular steatosis scorea	0.0****	4.0	0.5****	2.0
Fibrosis scorea	0	2	2	2

Values are means ± SE unless stated otherwise. GLP, glucagon-like peptide; HFCD, high fat, cholesterol, and carbohydrate diet (a model of nonalcoholic fatty liver disease and mild Type 2 diabetes).

^aValues are medians. For parametric data, statistical analyses were performed using one-way ANOVA followed by Holm-Šídák’s multiple-comparisons test. Parametric left-censored data and nonparametric data were analyzed using the Kruskal-Wallis test followed by Dunn’s test.

^*P < 0.05,

^**P < 0.01,

^***P < 0.001, and

^****P < 0.0001 vs. vehicle-HFCD-fed group.